Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action

od Wudhikarn, Kitsada, Wills, Beatriz, Lesokhin, Alexander M.
izdano v Best Pract Res Clin Haematol (2020)

Inhibition of Chemokine Expression by Adenovirus Early Region Three (E3) Genes

od Lesokhin, Alexander M., Delgado-Lopez, Fernando, Horwitz, Marshall S.
Izdano 2002

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy

od Lesokhin, Alexander M., Merghoub, Taha, Wolchok, Jedd D.
Izdano 2013

Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma

od Lesokhin, Alexander M., Bal, Susan, Badros, Ashraf Z.
izdano v Cancer Immunol Res (2019)

Hiding the road signs that lead to tumor immunity

od Schaer, David A., Lesokhin, Alexander M., Wolchok, Jedd D.
Izdano 2011

Clinical Development of PD-1 Blockade in Hematologic Malignancies

od Pianko, Matthew J., Goldberg, Aaron D., Lesokhin, Alexander M.
izdano v Cancer J (2018)

Facts and Hopes in Immunotherapy of Lymphoma and Myeloma

od Pianko, Matthew J., Moskowitz, Alison J., Lesokhin, Alexander M.
izdano v Clin Cancer Res (2017)

Immune checkpoint blockade for hematologic malignancies: a review

od Pianko, Matthew J., Liu, Yuzhou, Bagchi, Srishti, Lesokhin, Alexander M.
izdano v Stem Cell Investig (2017)

Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and “Miliary” Liver Lesions: A Case Report

od Gonzalez-Aguirre, Adrian J., Lin, Oscar, Cho, Christina, Lesokhin, Alexander M., Maybody, Majid
izdano v J Gastrointest Dig Syst (2016)

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

od Badros, Ashraf Z., Ma, Ning, Rapoport, Aaron P., Lederer, Emily, Lesokhin, Alexander M.
izdano v Blood Adv (2019)

Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpati...

od Liu, Yuzhou, Han, Hedong, Shah, Gunjan, Giralt, Sergio, Landgren, C. Ola, He, Jia, Lesokhin, Alexander M.
izdano v Biol Blood Marrow Transplant (2018)

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

od Mailankody, Sham, Korde, Neha, Lesokhin, Alexander M., Lendvai, Nikoletta, Hassoun, Hani, Stetler-Stevenson, Maryalice, Landgren, Ola
izdano v Nat Rev Clin Oncol (2015)

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

od Cohen, Adam D., Garfall, Alfred L., Dogan, Ahmet, Lacey, Simon F., Martin, Chris, Lendvai, Nikoletta, Vogl, Dan T., Spear, Matthew, Lesokhin, Alexander M.
izdano v Blood Adv (2019)

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

od Martin, Thomas, Baz, Rachid, Benson, Don M., Lendvai, Nikoletta, Wolf, Jeffrey, Munster, Pamela, Lesokhin, Alexander M., Wack, Claudine, Charpentier, Eric, Campana, Frank, Vij, Ravi
izdano v Blood (2017)

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

od Hirschhorn-Cymerman, Daniel, Rizzuto, Gabrielle A., Merghoub, Taha, Cohen, Adam D., Avogadri, Francesca, Lesokhin, Alexander M., Weinberg, Andrew D., Wolchok, Jedd D., Houghton, Alan N.
Izdano 2009

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

od Nakahara, Takeshi, Uchi, Hiroshi, Lesokhin, Alexander M., Avogadri, Francesca, Rizzuto, Gabrielle A., Hirschhorn-Cymerman, Daniel, Panageas, Katherine S., Merghoub, Taha, Wolchok, Jedd D., Houghton, Alan N.
Izdano 2010

A phase 2 single-center study of carfilzomib 56 mg/m(2) with or without low-dose dexamethasone in relapsed multiple myeloma

od Lendvai, Nikoletta, Hilden, Patrick, Devlin, Sean, Landau, Heather, Hassoun, Hani, Lesokhin, Alexander M., Tsakos, Ioanna, Redling, Kaitlyn, Koehne, Guenther, Chung, David J., Schaffer, Wendy L., Giralt, Sergio A.
izdano v Blood (2014)

T cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy

od Chung, David J., Pronschinske, Katherine B., Shyer, Justin A., Sharma, Sneh, Leung, Samantha, Curran, Shane A., Lesokhin, Alexander M., Devlin, Sean M., Giralt, Sergio A., Young, James W.
izdano v Cancer Immunol Res (2015)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response

od Rizzuto, Gabrielle A., Merghoub, Taha, Hirschhorn-Cymerman, Daniel, Liu, Cailian, Lesokhin, Alexander M., Sahawneh, Diana, Zhong, Hong, Panageas, Katherine S., Perales, Miguel-Angel, Altan-Bonnet, Grégoire, Wolchok, Jedd D., Houghton, Alan N.
Izdano 2009

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype

od Hirschhorn-Cymerman, Daniel, Budhu, Sadna, Kitano, Shigehisa, Liu, Cailian, Zhao, Feng, Zhong, Hong, Lesokhin, Alexander M., Avogadri-Connors, Francesca, Yuan, Jianda, Li, Yanyun, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Izdano 2012